

November 15, 2019

Novartis Pharma AG  
CH-4002, Basel, Switzerland

Reference: EudraCT 2013-000256-18/ Novartis Protocol ID CRAD001N2202

A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability and efficacy of orally administered QAL964 in patients with active rheumatoid arthritis on stable doses of methotrexate and with inadequate response to methotrexate

Trial CRAD001N2202 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.